Top

World Journal of Urology

Published in:

01-12-2024 | Apalutamide | Original Article

Real-world analysis of apalutamide-associated skin rash in Chinese patients with prostate cancer

Authors: Zhen Yang, Yuan Shao, Hua Huang, Yang Liu, Zeyuan Wang, Yong Wang

Published in: World Journal of Urology | Issue 1/2024

Abstract

Purpose

This study aimed to explore the clinical characteristics of apalutamide-associated skin rash and management of skin rash in real-world Chinese patients with prostate cancer.

Methods

We investigated 138 patients with prostate cancer who received apalutamide in the Second Hospital of Tianjin Medical University from January 2022 to March 2023. The primary end points were the incidence of skin rash and the time to skin rash. The second end points were the grade of skin rash, the time to remission, the rate of recurrence of skin rash, clinical risk factors and management of skin rash.

Results

One hundred patients were analyzed. Patients were a median of 73 years old (IQR 68–77.75). Thirty-two patients (32%) developed apalutamide‑associated skin rash. The median time to incidence and remission of skin rash were 57.5 and 11.5 days, respectively. Of 32 skin rash, 27 patients had apalutamide therapy maintained after rash remission. There were seven patients having recurrence of skin rash. By multivariable logistic regression analysis, we revealed that hypertension history (OR 3.22, 95% CI 1.09–9.53, p = 0.035), bad life-styles (OR 3.29, 95% CI 1.11–9.8, p = 0.032), ECOG ≥ 1 (OR 3.92, 95% CI 1.33–11.55, p = 0.013), and high tumor burden (OR 3.13, 95% CI 1.07–9.14, p = 0.037) were independently associated with higher incidence of skin rash.

Conclusion

Nearly one-third of Chinese patients experienced skin rash after taking apalutamide in our study. The poor health patients might have a higher incidence of apalutamide-associated skin rash.

Available only for authorised users

Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7–33. https://doi.org/10.3322/caac.21708CrossRefPubMed

Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R et al (2022) Cancer incidence and mortality in China, 2016. J Natl Cancer Center 2:1–9. https://doi.org/10.1016/j.jncc.2022.02.002CrossRef

Ma CG, Ye DW, Li CL, Zhou FJ, Yao XD, Zhang SL et al (2008) Epidemiology of prostate cancer from three centers and analysis of the first-fine hormonal therapy for the advanced disease. Zhonghua wai ke za zhi [Chin J Surg] 46:921–925PubMed

Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. JAMA 294:238–244. https://doi.org/10.1001/jama.294.2.238CrossRefPubMed

Sathianathen NJ, Koschel S, Thangasamy IA, Teh J, Alghazo O, Butcher G et al (2020) Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Eur Urol 77:365–372. https://doi.org/10.1016/j.eururo.2019.09.004CrossRefPubMed

Marchioni M, Di Nicola M, Primiceri G, Novara G, Castellan P, Paul AK et al (2020) New antiandrogen compounds compared to docetaxel for metastatic hormone sensitive prostate cancer: results from a network meta-analysis. J Urol 203:751–759. https://doi.org/10.1097/JU.0000000000000636CrossRefPubMed

Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A et al (2012) ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 72:1494–1503. https://doi.org/10.1158/0008-5472.Can-11-3948CrossRefPubMedPubMedCentral

Chi KN, Chowdhury S, Bjartell A, Chung BH, de Santana P, Gomes AJ, Given R et al (2021) Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 39:2294–2303. https://doi.org/10.1200/JCO.20.03488CrossRefPubMed

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378:1408–1418. https://doi.org/10.1056/NEJMoa1715546CrossRefPubMed

10.

Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 79:263–282. https://doi.org/10.1016/j.eururo.2020.09.046CrossRefPubMed

11.

Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R et al (2022) NCCN guidelines(R) insights: prostate cancer, version 1.2023. J Natl Compr Canc Netw 20:1288–1298. https://doi.org/10.6004/jnccn.2022.0063CrossRefPubMed

12.

Chi KN, Agarwal N, Bjartell A, Chung BH, de Santana P, Gomes AJ, Given R et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381:13–24. https://doi.org/10.1056/NEJMoa1903307CrossRefPubMed

13.

Tohi Y, Kato T, Fukuhara H, Kobayashi K, Ohira S, Ikeda K et al (2022) Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium. Int J Clin Oncol 27:1348–1355. https://doi.org/10.1007/s10147-022-02183-zCrossRefPubMed

14.

Ji C, Guha M, Zhu X, Whritenour J, Hemkens M, Tse S et al (2020) Enzalutamide and apalutamide. In vitro chemical reactivity studies and activity in a mouse drug allergy model. Chem Res Toxicol 33:211–222. https://doi.org/10.1021/acs.chemrestox.9b00247CrossRefPubMed

15.

Uemura H, Koroki Y, Iwaki Y, Imanaka K, Kambara T, Lopez-Gitlitz A et al (2020) Skin rash following administration of apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study. BMC Urol 20:139. https://doi.org/10.1186/s12894-020-00689-0CrossRefPubMedPubMedCentral

16.

T’Jollyn H, Ackaert O, Chien C, Lopez-Gitlitz A, McCarthy S, Ruixo CP et al (2022) Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study. Cancer Chemother Pharmacol 89:629–641. https://doi.org/10.1007/s00280-022-04427-1CrossRefPubMed

17.

Perez-Ruixo C, Ackaert O, Ouellet D, Chien C, Uemura H, Olmos D et al (2020) Efficacy and safety exposure–response relationships of apalutamide in patients with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 26:4460–4467. https://doi.org/10.1158/1078-0432.Ccr-20-1041CrossRefPubMed

18.

Sasaki D, Hatakeyama S, Tanaka T, Okamoto T, Yoneyama T, Ohyama C (2022) Impact of body size on skin-related adverse events in advanced prostate cancer treated with apalutamide: a multicenter retrospective study. Int J Urol 29:772–773. https://doi.org/10.1111/iju.14860CrossRefPubMed

19.

Katsuta M, Kimura T, Tashiro K, Murakami M, Hata K, Yanagisawa T et al (2022) Low body weight as a risk factor for apalutamide-related cutaneous adverse events. Anticancer Res 42:2023–2028. https://doi.org/10.21873/anticanres.15682CrossRefPubMed

20.

Pan A, Reingold RE, Zhao JL, Moy A, Kraehenbuehl L, Dranitsaris G et al (2022) Dermatological adverse events in prostate cancer patients treated with the androgen receptor inhibitor apalutamide. J Urol 207:1010–1019. https://doi.org/10.1097/JU.0000000000002425CrossRefPubMedPubMedCentral

Title: Real-world analysis of apalutamide-associated skin rash in Chinese patients with prostate cancer
Authors: Zhen Yang
Yuan Shao
Hua Huang
Yang Liu
Zeyuan Wang
Yong Wang
Publication date: 01-12-2024
Publisher: Springer Berlin Heidelberg
Keywords: Apalutamide
Prostate Cancer
Prostate Cancer
Published in: World Journal of Urology / Issue 1/2024
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-024-04880-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Real-world analysis of apalutamide-associated skin rash in Chinese patients with prostate cancer

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Treatment patterns and prognosis in patients with Bacillus Calmette–Guérin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysis

Comparison of metabolic parameters between pure-uric acid and mixed-uric acid kidney stone formers

Cost-effectiveness of quality improvement intervention to reduce time between CT-detection and ureteroscopic laser fragmentation in acute symptomatic ureteric stones management

PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions

Factors related to acupuncture response in patients with chronic prostatitis/chronic pelvic pain syndrome: secondary analysis of a randomized controlled trial

Longitudinal evaluation of MRI findings, including quantitative apparent diffusion coefficient values, might be necessary to predict disease progression in patients with prostate cancer on active surveillance